Related by context. Frequent words. (Click for all words.) 76 Advanced Prostate Cancer 74 Elderly Patients 71 Lung Cancer Patients 71 Prostate Cancer Patients 71 Patients Undergoing 70 Well Tolerated 70 Patients Treated 70 Clinical Trial Results 70 Pediatric Patients 69 Breast Cancer Patients 69 Chronic Hepatitis C 69 Monotherapy 69 Newly Diagnosed 69 Tolerability 68 Cognitive Decline 68 Diabetic Patients 68 Gastric Cancer 68 Metastatic Colorectal Cancer 68 Bladder Cancer 68 Metastatic Breast Cancer 67 Heart Failure Patients 67 Stomach Cancer 67 Breast Cancer Treatment 67 Chronic Lymphocytic Leukemia 67 Ischemic 67 Overactive Bladder 67 Postmenopausal Women 67 Drug Candidate 67 Varicose Veins 66 Cardiovascular Events 66 Benign Prostatic Hyperplasia 66 Kidney Stones 66 II Clinical Trial 66 Post Operative 66 Reduces Risk 66 Pivotal Phase 66 Tumor Growth 66 Combination Therapy 65 Gum Disease 65 Blood Vessels 65 Metastatic Melanoma 65 Single Dose 65 Hormone Therapy 65 Blood Clots 65 Autoimmune Disease 65 Low Dose 65 Phase III Clinical Trial 65 Phase III Trial 65 Completes Enrollment 65 Capecitabine 65 Increases Risk 64 Preclinical Data 64 Idiopathic Pulmonary Fibrosis 64 Metastatic 64 Urinary Incontinence 64 Recombinant Human 64 Increased Risk 64 Venous Thromboembolism 64 Significantly Reduces 64 Chronic Heart Failure 64 Glioma 64 Epratuzumab 64 Erlotinib 64 Drug Resistant 64 Dialysis Patients 64 Blood Thinner 64 Prostate Cancer Treatment 64 Pivotal Phase III 63 Initiate Phase 63 Bevacizumab 63 Cholesterol Drug 63 Cancer Treatments 63 Allergic Rhinitis 63 Golimumab 63 Treatable 63 Survival Rates 63 Regimens 63 Pivotal Trial 63 Anti TNF 63 Bortezomib 63 Meta Analysis 63 Hepatitis C Virus 63 Atopic Dermatitis 63 Vertebroplasty 63 Prostate Cancer Risk 63 Breast Cancer Risk 62 Acute Coronary Syndromes 62 C Reactive Protein 62 Ear Infections 62 Presents Positive 62 Early Diagnosis 62 Shows Promise 62 Breast Reconstruction 62 Randomized Controlled Trial 62 Brain Cells 62 FDA Clears 62 Thyroid Cancer 62 Alemtuzumab 62 Trastuzumab 62 Brain Tumors 62 Adalimumab